Immunovant Stock Net Income
| IMVT Stock | USD 28.73 1.57 5.78% |
Immunovant fundamentals help investors to digest information that contributes to Immunovant's financial success or failures. It also enables traders to predict the movement of Immunovant Stock. The fundamental analysis module provides a way to measure Immunovant's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunovant stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -259.3 M | -246.4 M | |
| Net Loss | (450.00) | (472.50) | |
| Net Loss | -259.3 M | -450 | |
| Net Income Per E B T | 1.00 | 0.80 |
Immunovant | Net Income |
Immunovant Company Net Income Analysis
Immunovant's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Immunovant Net Income | (259.34 M) |
Most of Immunovant's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunovant is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Immunovant Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Immunovant is extremely important. It helps to project a fair market value of Immunovant Stock properly, considering its historical fundamentals such as Net Income. Since Immunovant's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunovant's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunovant's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Immunovant Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Immunovant reported net income of (259.34 Million). This is 175.99% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 145.42% higher than that of the company.
Immunovant Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunovant's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunovant could also be used in its relative valuation, which is a method of valuing Immunovant by comparing valuation metrics of similar companies.Immunovant is currently under evaluation in net income category among its peers.
Immunovant ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immunovant's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immunovant's managers, analysts, and investors.Environmental | Governance | Social |
Immunovant Institutional Holders
Institutional Holdings refers to the ownership stake in Immunovant that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Immunovant's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunovant's value.| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.6 M | Geode Capital Management, Llc | 2024-09-30 | 1.5 M | Paradigm Biocapital Advisors Lp | 2024-09-30 | 1.4 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.4 M | Baker Bros Advisors Lp | 2024-09-30 | 1.2 M | Rock Springs Capital Management Lp | 2024-06-30 | 1.2 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.2 M | Logos Global Management Lp | 2024-06-30 | 1.1 M | Nuveen Asset Management, Llc | 2024-06-30 | 1.1 M | Fmr Inc | 2024-09-30 | 12.5 M | Vanguard Group Inc | 2024-09-30 | 6.7 M |
Immunovant Fundamentals
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.55 | ||||
| Current Valuation | 3.74 B | ||||
| Shares Outstanding | 146.78 M | ||||
| Shares Owned By Insiders | 55.70 % | ||||
| Shares Owned By Institutions | 54.62 % | ||||
| Number Of Shares Shorted | 13.02 M | ||||
| Price To Book | 9.39 X | ||||
| EBITDA | (269.98 M) | ||||
| Net Income | (259.34 M) | ||||
| Cash And Equivalents | 427.2 M | ||||
| Cash Per Share | 3.66 X | ||||
| Total Debt | 138 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 21.48 X | ||||
| Book Value Per Share | 3.06 X | ||||
| Cash Flow From Operations | (214.23 M) | ||||
| Short Ratio | 16.69 X | ||||
| Earnings Per Share | (2.21) X | ||||
| Target Price | 48.93 | ||||
| Number Of Employees | 207 | ||||
| Beta | 0.71 | ||||
| Market Capitalization | 4.22 B | ||||
| Total Asset | 666.37 M | ||||
| Retained Earnings | (825.68 M) | ||||
| Working Capital | 617.16 M | ||||
| Net Asset | 666.37 M |
About Immunovant Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunovant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunovant using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunovant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.